Compare Illumina, Inc. (ILMN) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Okta, Inc. — how do they compare? Illumina, Inc. trades at $190.08 (market cap $27.94B), while Okta, Inc. trades at $140.41 (market cap $25.79B). The key difference: Illumina, Inc. and Okta, Inc. are close in size by market cap, and Illumina, Inc. is trading nearer its 52-week high, Okta, Inc. nearer its low. Which is the better fit depends on your goals.
| ILMN | OKTA | |
|---|---|---|
Market Cap | $27.94B | $25.79B |
Sector | Health | Technology |
52-Week High | $194.33 | $154.62 |
52-Week Low | $91.00 | $62.93 |
Enterprise Value | $29.33B | $23.62B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
OKTA trades at $150.64, up 0.86% today, with a bullish technical outlook supported by moving averages and strong institutional sentiment. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $0.96. Revenue growth accelerated to $2.61B in 2025, achieving positive net income of $28M after years of losses, while operating cash flow surged to $750M. Recent news highlights AI-driven cybersecurity demand boosting Okta's identity protection solutions.
Outlook is positive given earnings momentum and sector tailwinds, but high valuation multiples (P/E 108.22) pose risks if growth slows. Analyst consensus is strongly bullish with a $125.78 price target, though competitive pressures and macroeconomic volatility remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
